Differential Response to Low-Dose Dopamine or Low-Dose Nesiritide in Acute Heart Failure With Reduced or Preserved Ejection Fraction Results From the ROSE AHF Trial (Renal Optimization Strategies Evaluation in Acute Heart Failure)

摘要

Background-The ROSE AHF trial (Renal Optimization Strategies Evaluation in Acute Heart Failure) found that when compared with placebo, neither low-dose dopamine (2 mu g/kg per minute) nor low-dose nesiritide (0.005 mu g/kg per minute without bolus) enhanced decongestion or preserved renal function in AHF patients with renal dysfunction. However, there may be differential responses to vasoactive agents in AHF patients with reduced versus preserved ejection fraction (EF). This post hoc analysis examined potential interaction between treatment effect and EF (EF <= 40% versus >40%) on the ROSE AHF end points.